Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 5/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16690383 | 0.88 | NOTUM (0.38) | MAPTHTTTHRB | |
| SCHEMBL16690429 | 0.85 | MAOB (0.45) | THRB | |
| SCHEMBL16690361 | 0.85 | KDM5A (0.35) | MAPTTP53TSHRKDM4EMEN1 | |
| SCHEMBL16690349 | 0.85 | NPC1 (0.39) | MAPTLMNANPSR1HTTTHRB | |
| SCHEMBL18053069 | 0.84 | THRA (0.35) | THRBKDM5AKDM4CKDM5B | |
| SCHEMBL18053070 | 0.84 | KDM5A (0.34) | MAPTTP53KDM5AKDM4CKDM5B | |
| SCHEMBL16690411 | 0.84 | KDM4A (0.33) | KDM5AKDM4CKDM5BKDM4AKDM2B | |
| SCHEMBL16690415 | 0.83 | P2RX3 (0.34) | — | |
| SCHEMBL16690345 | 0.82 | KDM4C (0.43) | KDM4ETHRBKDM5AKDM4CKDM5B | |
| SCHEMBL18053079 | 0.81 | KDM5A (0.37) | KDM4EKDM5AKDM4CKDM5BKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2015064727-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | 住友化学株式会社 | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160249617-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | TCOF1, TAOK2, CYC1 | MAPT 4430/4885TP53 4149/4885LMNA 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.